Regulus Therapeutics Inc. (RGLS)

$ 0.441
-0.03 (-6.57%)
Symbol RGLS
Price $ 0.441
Beta 2.197
Volume Avg. 1.54M
Market Cap 0.04B
Shares () -
52 Week Range 0.425-2.32
1y Target Est -
DCF Unlevered RGLS DCF ->
DCF Levered RGLS LDCF ->
ROE -60.96% Strong Sell
ROA -30.08% Strong Sell
Operating Margin -
Debt / Equity 34.45% Neutral
P/E -
P/B 0.92 Buy


Consensus EPS

Upgrades & Downgrades

Latest RGLS news

Mr. Joseph Hagan
Nasdaq Global Market

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.